Clinical Significance of Gene Amplification in Metastatic or Locally Advanced Gastric Cancer Treated with First-line Fluoropyrimidine and Platinum Combination Chemotherapy

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2019 Oct 1

PMID 31564805

Citations 5

Authors

Seyoung Seo

Min-Hee Ryu

Baek-Yeol Ryoo

Yangsoon Park

Young Soo Park

Young-Soon Na

Chae-Won Lee

Ju-Kyung Lee

Yoon-Koo Kang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the clinical significance of gene amplification in patients with gastric cancer in the palliative setting.

Methods: amplification was assessed using fluorescence hybridization (FISH) in 50 patients and quantitative polymerase chain reaction (qPCR) in 326 patients; 259 patients treated with first-line fluoropyrimidine and platinum were included for survival analysis.

Results: The results of FISH and qPCR indicated that the c-/CEP7 ratio was correlated with gene copy number. The optimal cutoff value for the copy number using qPCR to detect gene amplification with FISH was 5 (κ=0.778, P<0.001). Twenty-one out of 326 patients (6.4%) were identified as amplification with a copy number of >5 detected by qPCR. -amplified gastric cancer was associated with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of ≥2 (33.3% . 10.5% P=0.007), peritoneal metastasis (76.2% . 46.2%, P=0.008), and elevated bilirubin levels (28.6% . 7.3%, P=0.006). The median overall survival (OS) and progression-free survival (PFS) were 11.9 and 5.6 months, respectively. -amplified gastric cancer was not associated with survival outcomes [hazard ratio (HR)=0.68, 95% confidence interval (95% CI): 0.35-1.32, P=0.254 for PFS; HR=0.68, 95% CI: 0.35-1.32, P=0.251 for OS].

Conclusions: qPCR can be used to detect gene amplification. amplification was not a predictor of poor prognosis in patients with metastatic or unresectable gastric cancer.

Citing Articles

Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review.

Wei W, Hong Y, Deng Y, Wang G, Qiu J, Pan F World J Gastrointest Oncol. 2024; 16(8):3397-3409.

PMID: 39171189 PMC: 11334049. DOI: 10.4251/wjgo.v16.i8.3397.

Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer.

Wang L, Zhang W, Qiu Y, Wang F World J Gastrointest Oncol. 2024; 16(6):2781-2792.

PMID: 38994139 PMC: 11236228. DOI: 10.4251/wjgo.v16.i6.2781.

Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer.

Zhang Z, Yu Y, Xie T, Qi C, Zhang X, Shen L Cancer Med. 2023; 12(19):19583-19594.

PMID: 37772487 PMC: 10587944. DOI: 10.1002/cam4.6575.

Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin.

Zhao Y, Ma L, Yang Z, Wang F, Wang H, Dang J World J Gastrointest Oncol. 2023; 15(2):286-302.

PMID: 36908323 PMC: 9994047. DOI: 10.4251/wjgo.v15.i2.286.

Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.

Tong A, Di X, Zhao X, Liang X Front Genet. 2023; 14:952379.

PMID: 36873929 PMC: 9978161. DOI: 10.3389/fgene.2023.952379.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

Kim C, Kim J, Kahng H, Choi E . Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma. Ann Surg Oncol. 2007; 14(5):1565-74. DOI: 10.1245/s10434-006-9320-5. View

Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, Nakanishi I . Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest. 1998; 78(9):1143-53. View

Lengyel E, Prechtel D, Resau J, Gauger K, Welk A, Lindemann K . C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2004; 113(4):678-82. DOI: 10.1002/ijc.20598. View

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y . Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016; 34(13):1448-54. DOI: 10.1200/JCO.2015.63.5995. View

Lee H, Kim M, Lee H, Jung E, Yang H, Lee B . MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012; 107(2):325-33. PMC: 3394975. DOI: 10.1038/bjc.2012.237. View

Shah M, Cho J, Tan I, Tebbutt N, Yen C, Kang A . A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist. 2016; 21(9):1085-90. PMC: 5016069. DOI: 10.1634/theoncologist.2016-0038. View

Walker F, Kermorgant S, Darai E, Madelenat P, Cremieux A, Henin D . Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus. Clin Cancer Res. 2003; 9(1):273-84. View

10.

Lennerz J, Kwak E, Ackerman A, Michael M, Fox S, Bergethon K . MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011; 29(36):4803-10. PMC: 3255989. DOI: 10.1200/JCO.2011.35.4928. View

11.

Li Y, Chen C, He Y, Cai S, Yang D, He W . Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012; 106(3):304-10. DOI: 10.1002/jso.23008. View

12.

Koo D, Ryoo B, Kim H, Ryu M, Lee S, Moon J . A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models. Cancer Chemother Pharmacol. 2011; 68(4):913-21. DOI: 10.1007/s00280-011-1561-8. View

13.

Janjigian Y, Tang L, Coit D, Kelsen D, Francone T, Weiser M . MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 2011; 20(5):1021-7. PMC: 3690490. DOI: 10.1158/1055-9965.EPI-10-1080. View

14.

Trusolino L, Bertotti A, Comoglio P . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010; 11(12):834-48. DOI: 10.1038/nrm3012. View

15.

An X, Wang F, Shao Q, Wang F, Wang Z, Chen C . MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. Cancer. 2014; 120(5):675-82. DOI: 10.1002/cncr.28454. View

16.

Catenacci D, Tebbutt N, Davidenko I, Murad A, Al-Batran S, Ilson D . Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(11):1467-1482. PMC: 5898242. DOI: 10.1016/S1470-2045(17)30566-1. View

17.

Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald M, Stratowa C . Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005; 11(23):8348-57. DOI: 10.1158/1078-0432.CCR-05-0841. View

18.

Di Renzo M, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L . Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995; 1(2):147-54. View

19.

Fontes Jardim D, Gagliato D, Falchook G, Janku F, Zinner R, Wheler J . MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014; 5(7):1837-45. PMC: 4039117. DOI: 10.18632/oncotarget.1828. View

20.

Kang Y, Muro K, Ryu M, Yasui H, Nishina T, Ryoo B . A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs. 2013; 32(2):355-61. DOI: 10.1007/s10637-013-0057-2. View